NewsBenzingaAytu BioPharma Q4 EPS $0.00 and Sales $16.106M Beat $12.276M Estimate Aytu BioPharma Q4 EPS $0.00 and Sales $16.106M Beat $12.276M Estimate Benzinga 2026.09.22 20:06 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Overweight on Essential Properties, Lowers Price Target to $30 Morgan Stanley Maintains Equal-Weight on Sportradar Gr, Lowers Price Target to $13.5 Morgan Stanley Maintains Underweight on Simmons First Ntl, Raises Price Target to $27 Wells Fargo Maintains Equal-Weight on EPR Properties, Lowers Price Target to $56 Analyst Sees Billions in Walmart's Next Big Advertising Opportunity Morgan Stanley Maintains Equal-Weight on Red Rock Resorts, Lowers Price Target to $59
